Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Arthur Kavanaugh"'
Autor:
Laura C. Coates, T. Nurminen, Philip S. Helliwell, Désirée van der Heijde, Lars Bauer, Joseph F. Merola, William Tillett, Oliver FitzGerald, Philip J. Mease, Arthur Kavanaugh, Alice B. Gottlieb, Bengt Hoepken
Publikováno v:
Abstracts accepted for Publication.
Background: Psoriatic arthritis Disease activity Score (PASDAS),1Disease activity index for Psoriatic arthritis (DAPSA),2 and the minimal disease activity (MDA) criteria3 are instruments recommended for evaluating disease activity (DA) in psoriatic a
Autor:
Elizabeth C. Hsia, Diane D. Harrison, Soumya D. Chakravarty, D. Parenti, Kim Hung Lo, Philip J. Mease, L. Kim, S. Kafka, Arthur Kavanaugh, M. Elaine Husni
Publikováno v:
Abstracts accepted for Publication.
Background GO-VIBRANT is a Phase 3 trial of intravenous (IV) golimumab (GLM) in adult patients (pts) with active psoriatic arthritis (PsA). Clinically meaningful improvements in skin and nail psoriasis (PsO) and in Dermatology Life Quality index (DLQ
Autor:
Laura C. Cappelli, Jeff Greenberg, Dimitrios A. Pappas, Connie Chen, Kimberly J. Dandreo, Carol J. Etzel, Ann Madsen, Jamie Geier, Heather J. Litman, Arthur Kavanaugh, Andrea Shapiro, Christine J. Barr, Clifton O. Bingham, Alina Onofrei, Joel M. Kremer, Carol A. Connell
Publikováno v:
Oral Presentations.
Background: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Real-world data (RWD) complement clinical trial data in assessing long-term safety. To our knowledge, this is the first long-term comparative RWD analysi
Autor:
Elizabeth C. Hsia, Yiying Zhou, Arthur Kavanaugh, Sergio Schwartzman, Soumya D. Chakravarty, Kim Hung Lo, Atul Deodhar, S. Kafka, Jocelyn H. Leu, M. Elaine Husni, Diane D. Harrison
Publikováno v:
Abstracts Accepted for Publication.
Background The GO-FURTHER, GO-VIBRANT, and GO-ALIVE randomized controlled trials evaluated the efficacy and safety of intravenous (IV) golimumab (GLM) in patients (pts) with active rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing
Autor:
Deepak Assudani, Christopher T. Ritchlin, B. Ink, Thomas Kumke, Richard B. Warren, Georg Schett, Arthur Kavanaugh, Jose U. Scher, Iain B. McInnes, Joseph F. Merola
Publikováno v:
Oral Presentations.
Background IL-17F shares structural homology and pro-inflammatory function with IL–17A. Preclinical and early clinical data support neutralisation of IL-17F, in addition to IL–17A, as a novel targeting approach in psoriatic disease. Objectives Th
Autor:
Melania Martínez-Morillo, Lourdes Mateo Soria, Oswald Quehenberger, Roxana Coras, Arthur Kavanaugh, Rekha Narasimhan, Monica Guma
Publikováno v:
Poster Presentations.
Background Elderly-onset RA (EORA), which is defined as rheumatoid arthritis (RA) with an onset at >60 years of age, and polymyalgia rheumatica (PMR) are common rheumatic diseases in the elderly. Eicosanoids are biological lipids that serve a specifi
Publikováno v:
Psoriatic arthritis.
Background Psoriatic arthritis (PsA) is a heterogeneous disease involving multiple domains including the musculoskeletal system and the skin. The disease may have a significant impact on various aspects of quality of life including sexuality. Objecti
Autor:
Rubén Queiro, Philip J. Mease, Dafna D. Gladman, Arthur Kavanaugh, Alexis Ogdie, L. Teng, Benoit Guerette, Michele Brunori, Frank Behrens
Publikováno v:
Psoriatic arthritis.
Background Therapeutic targets for long-term control of psoriatic arthritis (PsA) include the achievement of remission (REM) or low disease activity (LDA), as measured by the Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA).1 Objectiv
Autor:
Elizabeth C. Hsia, M. Elaine Husni, Philip J. Mease, Soumya D. Chakravarty, Kim Hung Lo, S. Kafka, Arthur Kavanaugh, Diane D. Harrison, Stephen Xu
Publikováno v:
Saturday, 15 June 2019.
Background GO-VIBRANT is a Phase 3 trial of intravenous (IV) golimumab (GLM), an anti-tumor necrosis factor alpha (TNFα) monoclonal antibody, in adult patients (pts) with active psoriatic arthritis (PsA). Objectives To assess if changes in Disease A
Autor:
Alice B. Gottlieb, Olivier Bénichou, Julie Birt, Arthur Kavanaugh, Matthew M. Hufford, C.-Y. Lin
Publikováno v:
Saturday, 16 JUNE 2018.
Background Psoriatic arthritis (PsA) is a chronic, systemic, autoimmune, inflammatory arthritis condition commonly associated with psoriasis. Several biologic therapies exist for the treatment of PsA, with varying degrees of efficacy and onset of act